For nearly seven years, Chika Anekwe, MD, MPH, has been on the front lines of obesity care at Massachusetts General Hospital Weight Center
Here is how many participants in each group hit specific milestones: 10% or more body weight loss: More participants achieved this with tirzepatide 15% or more body weight loss: Substantially more with tirzepatide 20% or more body weight loss: Significantly more with tirzepatide 25% or more body weight loss: 31.6% of tirzepatide users versus only 16.1% of semaglutide users Nearly twice as many people on tirzepatide achieved 25% or greater body weight loss compared to semaglutide
Calorie reduction and dietary changes can sometimes contribute to lower nutrient intake, which may leave people feeling fatigued or run down
NDA filing expected late 2026 / early 2027 Medicare GLP-1 Bridge Program: launches July 1, 2026
Important safety considerations include contraindications in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, caution in those with a history of pancreatitis, increased risk of gallbladder disease, potential for acute kidney injury with dehydration, and possible worsening of diabetic retinopathy with rapid glycemic improvement